Home
Our approach
We focus our science on respiratory health, rare diseases and specialty care, where our expertise and capabilities can deliver meaningful progress for people. We actively listen to patients, caregivers and healthcare professionals to understand the realities of living with disease and reflect these insights in how we develop and deliver our solutions.
This means investing for the long term in research and development, translating scientific knowledge into therapies that improve patients’ outcomes and lives. Our Paolo Chiesi Research Center in Parma (Italy) integrates with six other major research centers in Paris (France), Chippenham (UK), Cary (USA), Lidingo (Sweden), Shanghai (China), and Toronto (Canada).
Our focus is rooted in more than 90 years of scientific progress, from Chiesi’s founding in Italy in 1935 to our global presence today with therapies and solutions available in more than 100 countries. Our areas of focus reflect both urgent patient needs and the scientific expertise, capabilities and long-term commitment we bring to addressing it.
Our annual investment in R&D has doubled since 2021, reflected in tangible scientific output, including 6,324 worldwide patents and 36 first filings at the European Patent Office in 2025, ranking Chiesi as the leading Italian pharmaceutical company for R&D investment and 11th among European pharmaceutical companies
Corporate
Chiesi appoints David Khougazian as Group Chief Executive Officer to lead the next phase of innovation-driven growth
Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins…
Corporate
Chiesi Group delivers solid H1 2026 performance, combining growth, continued investment in innovation and positive economic impact across communities
HIGHLIGHTS H1 2026 revenues of €1.89 billion, up + 3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic…
Innovation
Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been…
Innovation
Chiesi receives European Marketing Authorisation for its Single Inhaler Triple Therapy delivered via NEXThaler® for the maintenance treatment of Asthma
Key Highlights This European Authorisation reinforces Chiesi’s commitment to provide a broad range of formulations and devices to asthma patients. NEXThaler® is a dry powder inhaler (DPI), specifically designed for Chiesi’s extrafine formulations. With the addition of the DPI in the asthma…
Innovation
Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)
PARMA, Italy – June 5, 2026 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the European Commission (EC) has approved lomitapide capsules for use in children 5…
Corporate
Chiesi completes the KalVista acquisition
Parma, Italy and Framingham, Mass., USA – 11 June, 2026 – Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group…
Corporate
Chiesi Group Announces New Chair and Vice Chair
Highlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations Maria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an…
Corporate
Chiesi to acquire KalVista Pharmaceuticals
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s…
Corporate
Chiesi's FY2025 results and a leadership transition
Highlights: Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs.…
Corporate
Chiesi selects Salesforce Agentforce Life Sciences
International biopharmaceutical leader accelerates digital transformation with AI-powered customer engagement, unified data, and next-generation integration capabilities APRIL 20, 2026 – Chiesi Group, an international biopharmaceutical group, has selected Salesforce’s Agentforce Life Sciences for…